Medical History of the Patients Before Anti-CD19-CAR T Cell Therapy

Thirteen R/R diffuse large B-cell lymphoma (DLBCL) and B-ALL patients were admitted in our hospital between August 2017 and July 2018. Seven of them were R/R DLBCL patients, while six of them were R/R B-ALL patients. They all received the anti-CD19 CAR-T cell therapy when they were diagnosed as R/R DLBCL or R/RB-ALL. No patients received hematopoietic stem cell transplant(HSCT) before the two kinds of CAR-T cell therapy. The cutoff date of data collection is August 31, 2020.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.